The stock of BriaCell Therapeutics Corp (BCTX) has gone down by -6.08% for the week, with a 23.86% rise in the past month and a 10.46% rise in the past quarter. The volatility ratio for the week is 10.17%, and the volatility levels for the past 30 days are 21.98% for BCTX. The simple moving average for the past 20 days is -8.11% for BCTX’s stock, with a -56.06% simple moving average for the past 200 days.
Is It Worth Investing in BriaCell Therapeutics Corp (NASDAQ: BCTX) Right Now?
Company’s 36-month beta value is 1.34.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCTX is 31.59M, and currently, short sellers hold a 1.42% ratio of that floaft. The average trading volume of BCTX on October 22, 2024 was 4.67M shares.
BCTX) stock’s latest price update
BriaCell Therapeutics Corp (NASDAQ: BCTX) has experienced a rise in its stock price by 6.13 compared to its previous closing price of 0.80. However, the company has seen a fall of -6.08% in its stock price over the last five trading days. globenewswire.com reported 2024-10-22 that PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer (MBC) study.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy.” The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at 10.19% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.85% of loss for the given period.
Volatility was left at 21.98%, however, over the last 30 days, the volatility rate increased by 10.17%, as shares surge +30.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.56% upper at present.
During the last 5 trading sessions, BCTX fell by -8.48%, which changed the moving average for the period of 200-days by -84.72% in comparison to the 20-day moving average, which settled at $0.9187. In addition, BriaCell Therapeutics Corp saw -85.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCTX starting from Lustig Marc, who purchase 902,935 shares at the price of $2.21 back on May 14 ’24. After this action, Lustig Marc now owns 2,542,935 shares of BriaCell Therapeutics Corp, valued at $2,000,001 using the latest closing price.
Stock Fundamentals for BCTX
The total capital return value is set at 63.64. Equity return is now at value -202.12, with -33.38 for asset returns.
Currently, EBITDA for the company is -22.37 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
In a nutshell, BriaCell Therapeutics Corp (BCTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
